Welcome to our dedicated page for TRxADE HEALTH news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on TRxADE HEALTH stock.
TRxADE Health, Inc. (MEDS) operates a pioneering web-based platform transforming pharmaceutical procurement through competitive supplier markets and data analytics. This news hub provides essential updates for stakeholders tracking the company’s impact on healthcare supply chain efficiency.
Key updates include strategic partnerships, platform enhancements, and financial performance. Access verified press releases about MEDS’ e-commerce innovations, regulatory milestones, and market expansion efforts.
Discover announcements about supplier network growth, analytics feature upgrades, and compliance achievements. Our curated news collection helps investors assess MEDS’ role in modernizing pharmaceutical purchasing through technology-driven solutions.
Bookmark this page for real-time updates on TRxADE Health’s initiatives in secure pharmaceutical transactions and data-driven procurement strategies. Stay informed about developments shaping the future of healthcare supply chain management.
TRxADE HEALTH INC. (NASDAQ:MEDS) will release its financial results for the first quarter of 2023 on May 8, 2023, after market close. The results will be discussed in a conference call at 5:00 p.m. Eastern time on the same day. Interested participants can join via a toll-free U.S. number or an international dial-in. TRxADE focuses on optimizing the retail pharmacy experience, utilizing technology to enhance drug procurement and patient engagement. The company serves over 14,500 members, promoting price transparency and offering telehealth services under the Bonum Health brand. A playback of the conference call will be accessible until June 8, 2023, providing further insights into the company's financial performance.
TRxADE Health, a digital healthcare services IT company, reported a 16% revenue increase to $11.4 million for the fiscal year 2022, up from $9.9 million in 2021. Key growth drivers included a 10% increase in revenues from the TRxADE Platform and a 46% rise from Trxade Prime, despite a 29% revenue decline in its Community Specialty Pharmacy unit. The firm's gross profit remained steady at 48%, and net losses narrowed to $3.9 million, down from $5.3 million in 2021. The company expanded its registered users by 8%, totaling over 14,400. A conference call is scheduled for March 27, 2023, to discuss these results.
FAQ
What is the current stock price of TRxADE HEALTH (MEDS)?
What is the market cap of TRxADE HEALTH (MEDS)?
